Evidence map›Paper›PMID 27752221›Full record

ReviewPharmaceutical medicine2016

Strategies and Systems-Level Interventions to Combat or Prevent Drug Counterfeiting: A Systematic Review of Evidence Beyond Effectiveness.

Racha Fadlallah, Fadi El-Jardali, Farah Annan, Hayat Azzam, Elie A Akl

Open access · hybridAbstract readReview
In one paragraph

Review in Pharmaceutical medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Acceptability of a Prime Vendor System in Public Healthcare Facilities in Tanzania.International journal of health policy and management · 2021
    Article
  12. Article
  13. Tackling the blind spot of poor-quality medicines in Universal Health Coverage.Journal of pharmaceutical policy and practice · 2020
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Racha FadlallahCenter for Systematic Review in Health Policy and Systems Research (SPARK), American University of Beirut, Beirut, Lebanon ; Department of Health Management and Policy, Faculty of Health Sciences, American University of Beirut, Riad-El-Solh Beirut, Beirut, 1107 2020 Lebanon.
Fadi El-JardaliCenter for Systematic Review in Health Policy and Systems Research (SPARK), American University of Beirut, Beirut, Lebanon ; Department of Health Management and Policy, Faculty of Health Sciences, American University of Beirut, Riad-El-Solh Beirut, Beirut, 1107 2020 Lebanon ; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON Canada.
Farah AnnanDepartment of Health Management and Policy, Faculty of Health Sciences, American University of Beirut, Riad-El-Solh Beirut, Beirut, 1107 2020 Lebanon.
Hayat AzzamDepartment of Health Management and Policy, Faculty of Health Sciences, American University of Beirut, Riad-El-Solh Beirut, Beirut, 1107 2020 Lebanon.
Elie A AklCenter for Systematic Review in Health Policy and Systems Research (SPARK), American University of Beirut, Beirut, Lebanon ; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON Canada ; Department of Internal Medicine, American University of Beirut, Beirut, Lebanon ; Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
American University of Beirut · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA recent systematic review suggested that drug registrations and onsite quality inspections may be effective in reducing the prevalence of counterfeit and substandard drugs. However, simply replicating the most effective interventions is problematic, as it denotes implementing the intervention without further adaptation.

objectiveThe aim was to systematically review the evidence beyond effectiveness for systems-level interventions to combat or prevent drug counterfeiting.

methodsWe conducted an extensive search, including an electronic search of 14 databases. We included studies examining the efficiency, feasibility, reliability, and economic outcomes of the interventions, as well as barriers and facilitators to their implementation. Two reviewers selected eligible studies and abstracted data in duplicate and independently. We synthesized the results narratively, stratified by type of intervention.

resultsOf 10,220 captured citations, 19 met our inclusion criteria. The findings suggest that the following may strengthen regulatory measures (e.g., registration): minimizing drug diversion, enhancing lines of communications, ensuring feedback on drug quality, and promoting strict licensing criteria. There is evidence that onsite quality surveillance and inspection systems may be efficient and cost-effective for preliminary testing of large samples of drugs. Laws and legislation need to be specific to counterfeit drugs, include firm penalties, address online purchasing of drugs, and be complemented by education of judges and lawyers. Public awareness and education should rely on multiple platforms and comprehensive and dedicated content. While product authentication technologies may be efficient and reliable in detecting counterfeit drugs in the supply chain, they require a strong information system infrastructure. As for pharmacovigilance systems, it is critical to tackle the issue of underreporting, to enhance their chances of success.

conclusionSeveral factors are critical to the successful design and implementation of systems-level interventions to combat or prevent drug counterfeiting. Policymakers need to take these into consideration to ensure success of these interventions.

Identifiers

PMID27752221
PMCPMC5045490
OpenAlexW2507395187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.